Seven years ago, David Mitchell was diagnosed with multiple myeloma and, as he approached retirement last year, the former head of a public policy advocacy firm in Washington, DC, decided to take on a cause — drug pricing. So he approached the Laura and John Arnold Foundation, a philanthropy that is funding various research and pilot projects aimed at reining in drug costs. With their backing, Mitchell on Wednesday launched Patients for Affordable Drugs, a group that is devoted to injecting patient voices into the complicated and raucous debate. We spoke with him about the effort and this is an edited version of the conversation.

Pharmalot: What prompted you to do this?

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy